Skip to main content

Advertisement

SpringerLink
Log in

The Parkinsonism-Hyperpyrexia Syndrome

  • TELL ME SOMETHING I NEED TO KNOW
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

The parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal complication seen in Parkinson’s disease (PD) patients, most commonly following reduction or cessation of antiparkinson medications. Clinically it resembles neuroleptic malignant syndrome with rigidity, pyrexia, and reduced conscious level. There may be features of autonomic instability, and serum creatine kinase (CK) may be elevated. Complications of PHS include acute renal failure, aspiration pneumonia, deep venous thrombosis/pulmonary embolism, and disseminated intravascular coagulation (DIC). Management consists of dopaminergic drug replacement, supportive measures, and treatment of complications. The prognosis is improved with early recognition and management. Mortality of up to 4% has been reported, but an additional one-third of patients have permanent sequelae. Patients and physicians should be warned against sudden reduction in antiparkinson medications. PHS should always be considered in a patient with parkinsonism who presents with an acute deterioration in symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Delay J, Pichot P, Lemperiere T, et al. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris). 1960;118(1):145–52.

    Google Scholar 

  2. Caroff SN, Mann SC, Campbell EC, et al. Neuroleptic malignant syndrome. In: Frucht SJ, Fahn S, editors. Movement disorder emergencies diagnosis and treatment. New York: Humana Press; 2005. p. 41–52.

    Google Scholar 

  3. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res. 1995;29:233–44. doi:10.1016/0022-3956(95)00007-R.

    Article  PubMed  CAS  Google Scholar 

  4. Kipps CM, Fung VS, Grattan-Smith P, et al. Movement disorder emergencies. Mov Disord. 2005;20:322–34. doi:10.1002/mds.20325.

    Article  PubMed  Google Scholar 

  5. Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44:748–54. doi:10.1016/S0006-3223(97)00530-1.

    Article  PubMed  CAS  Google Scholar 

  6. Keck PE Jr, Pope HG Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989;46:914–8.

    PubMed  Google Scholar 

  7. Toru M, Matsuda O, Makiguchi K, et al. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis. 1981;169:324–7. doi:10.1097/00005053-198105000-00011.

    Article  PubMed  CAS  Google Scholar 

  8. Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson’s disease and related disorders. Parkinsonism Relat Disord. 2003;9(Suppl 1):S31–41. doi:10.1016/S1353-8020(02)00122-0.

    Article  PubMed  Google Scholar 

  9. Konagaya M, Goto Y, Matsuoka Y, et al. Neuroleptic malignant syndrome-like condition in multiple system atrophy. J Neurol Neurosurg Psychiatry. 1997;63:120–1.

    Article  PubMed  CAS  Google Scholar 

  10. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–13.

    PubMed  CAS  Google Scholar 

  11. Mayeux R, Stern Y, Mulvey K, et al. Reappraisal of temporary levodopa withdrawal (“drug holiday”) in Parkinson’s disease. N Engl J Med. 1985;313:724–8.

    PubMed  CAS  Google Scholar 

  12. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multi-centre European study. Mov Disord. 2008; in press.

  13. Douglas A, Morris J. It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson’s disease. Age Ageing. 2006;35:640–1. doi:10.1093/ageing/afl096.

    Article  PubMed  Google Scholar 

  14. Gaig C, Marti MJ, Tolosa E, et al. Parkinsonism-hyperpyrexia syndrome not related to antiparkinsonian treatment withdrawal during the 2003 summer heat wave. J Neurol. 2005;252:1116–9. doi:10.1007/s00415-005-0798-8.

    Article  PubMed  CAS  Google Scholar 

  15. Grace JB, Thompson P. Neuroleptic malignant like syndrome in two patients on cholinesterase inhibitors. Int J Geriatr Psychiatry. 2006;21:193–4. doi:10.1002/gps.1441.

    Article  PubMed  CAS  Google Scholar 

  16. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson’s disease. Mov Disord. 2001;16:960–2. doi:10.1002/mds.1166.

    Article  PubMed  CAS  Google Scholar 

  17. Mizuta E, Yamasaki S, Nakatake M, et al. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology. 1993;43:1048–9.

    PubMed  CAS  Google Scholar 

  18. Shimada J, Sakakibara R, Uchiyama T, et al. Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient. Eur J Neurol. 2006;13:306–7. doi:10.1111/j.1468-1331.2006.01151.x.

    Article  PubMed  CAS  Google Scholar 

  19. Factor SA. Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson’s disease patient while actively treated with deep brain stimulation. Mov Disord. 2007;22:148–9. doi:10.1002/mds.21172.

    Article  PubMed  Google Scholar 

  20. Factor SA, Santiago A. Parkinsonism-hyperpyrexia syndrome in Parkinson’s disease. In: Movement disorder emergencies: Diagnosis and treatment . New York: Humana Press; 2005. p. 29–41.

  21. Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease. Neurology. 1999;52:777–81.

    PubMed  CAS  Google Scholar 

  22. Ueda M, Hamamoto M, Nagayama H, et al. Biochemical alterations during medication withdrawal in Parkinson’s disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry. 2001;71:111–3. doi:10.1136/jnnp.71.1.111.

    Article  PubMed  CAS  Google Scholar 

  23. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50:18–25.

    PubMed  CAS  Google Scholar 

  24. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or—dopaminergic malignant syndrome—due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9:175–8. doi:10.1016/S1353-8020(02)00035-4.

    Article  PubMed  Google Scholar 

  25. Hashimoto T, Tokuda T, Hanyu N, et al. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2003;9 Suppl 1:S25–30. doi:10.1016/S1353-8020(02)00119-0.

    Article  PubMed  Google Scholar 

  26. Ikebe S, Harada T, Hashimoto T, et al. Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003;9 Suppl 1:S47–9. doi:10.1016/S1353-8020(02)00123-2.

    Article  PubMed  Google Scholar 

  27. Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21. doi:10.1186/1750-1172-2-21.

    Article  PubMed  Google Scholar 

  28. Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome. Successful treatment with bromocriptine. J Am Med Assoc. 1983;249:386–8. doi:10.1001/jama.249.3.386.

    Article  CAS  Google Scholar 

  29. Sato Y, Asoh T, Metoki N, et al. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:574–6. doi:10.1136/jnnp.74.5.574.

    Article  PubMed  CAS  Google Scholar 

  30. Magdalinou KN, Martin A, Kessel B. Prescribing medications in Parkinson’s disease (PD) patients during acute admissions to a District General Hospital. Parkinsonism Relat Disord. 2007;13:539–40. doi:10.1016/j.parkreldis.2006.11.006.

    Article  PubMed  Google Scholar 

  31. Grosset K, Needleman F, MacPhee G, et al. Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov Disord. 2004;19:1370–4. doi:10.1002/mds.20210.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, G51 4TF, UK

    Edward J. Newman, Donald G. Grosset & Peter G. E. Kennedy

Authors
  1. Edward J. Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald G. Grosset
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter G. E. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter G. E. Kennedy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newman, E.J., Grosset, D.G. & Kennedy, P.G.E. The Parkinsonism-Hyperpyrexia Syndrome. Neurocrit Care 10, 136–140 (2009). https://doi.org/10.1007/s12028-008-9125-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-008-9125-4

Keywords

Search

Navigation